Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib

International Journal of Pharmaceutics

Volumn 436, Issue 1-2, 2012, Pages 127-134

  Minocha, Mukul ^a   Khurana, Varun ^a   Qin, Bin ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Brain; Breast cancer resistance protein (Bcrp1); Canertinib; Erlotinib; P glycoprotein (P gp); Pazopanib; Pharmacokinetics

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; CANERTINIB; ELACRIDAR; ERLOTINIB; GLYCOPROTEIN P; PAZOPANIB; VANDETANIB; ZOSUQUIDAR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; CELL LINE; DOGS; MALE; MICE; MORPHOLINES; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; SULFONAMIDES;

EID: 84865293397     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.05.038     Document Type: Article

References (33)

1. S. Agarwal, R. Sane, J.L. Gallardo, J.R. Ohlfest, and W.F. Elmquist Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J. Pharmacol. Exp. Ther. 334 2010 147 155
2. S. Agarwal, R. Sane, J.R. Ohlfest, and W.F. Elmquist The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain J. Pharmacol. Exp. Ther. 336 2011 223 233
3. P. Breedveld, J.H. Beijnen, and J.H. Schellens Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs Trends Pharmacol. Sci. 27 2006 17 24
4. P. Breedveld, D. Pluim, G. Cipriani, P. Wielinga, O. van Tellingen, A.H. Schinkel, and J.H. Schellens The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res. 65 2005 2577 2582
5. Y. Chen, S. Agarwal, N.M. Shaik, C. Chen, Z. Yang, and W.F. Elmquist P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J. Pharmacol. Exp. Ther. 330 2009 956 963
6. C. Erlichman, S.A. Boerner, C.G. Hallgren, R. Spieker, X.Y. Wang, C.D. James, G.L. Scheffer, M. Maliepaard, D.D. Ross, K.C. Bible, and S.H. Kaufmann The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res. 61 2001 739 748
7. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
8. M.E. Halatsch, U. Schmidt, J. Behnke-Mursch, A. Unterberg, and C.R. Wirtz Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours Cancer Treat. Rev. 32 2006 74 89
9. M. Hermanson, K. Funa, M. Hartman, L. Claesson-Welsh, C.H. Heldin, B. Westermark, and M. Nister Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res. 52 1992 3213 3219
10. M. Hubensack, C. Müller, P. Höcherl, S. Fellner, T. Spruss, G. Bernhardt, and A. Buschauer Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nudemice J. Cancer Res. Clin. Oncol. 134 2008 597 607
11. F.M. Iwamoto, K.R. Lamborn, H.I. Robins, M.P. Mehta, S.M. Chang, N.A. Butowski, L.M. Deangelis, L.E. Abrey, W.T. Zhang, M.D. Prados, and H.A. Fine Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) Neuro Oncol. 12 2010 855 861
12. S. Katragadda, B. Budda, B.S. Anand, and A.K. Mitra Role of efflux pumps and metabolising enzymes in drug delivery Expert Opin. Drug Deliv. 2 2005 683 705
13. E.M. Kemper, C. Cleypool, W. Boogerd, J.H. Beijnen, and O. van Tellingen The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice Cancer Chemother. Pharmacol. 53 2004 173 178
14. H. Kodaira, H. Kusuhara, J. Ushiki, E. Fuse, and Y. Sugiyama Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 333 2010 788 796
15. J.S. Lagas, R.A. van Waterschoot, R.W. Sparidans, E. Wagenaar, J.H. Beijnen, and A.H. Schinkel Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation Mol. Cancer Ther. 9 2010 319 326
16. D.S. Miller Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier Trends Pharmacol. Sci. 31 2010 246 254
17. K.H. Plate, G. Breier, H.A. Weich, and W. Risau Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 1992 845 848
18. J.W. Polli, K.L. Olson, J.P. Chism, L.S. John-Williams, R.L. Yeager, S.M. Woodard, V. Otto, S. Castellino, and V.E. Demby An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab. Dispos. 37 2009 439 442
19. M.D. Prados, K.R. Lamborn, S. Chang, E. Burton, N. Butowski, M. Malec, A. Kapadia, J. Rabbitt, M.S. Page, A. Fedoroff, D. Xie, and S.K. Kelley Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro Oncol. 8 2006 67 78
20. J.J. Raizer HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme J. Neurooncol. 74 2005 77 86
21. J.J. Raizer, L.E. Abrey, A.B. Lassman, S.M. Chang, K.R. Lamborn, J.G. Kuhn, W.K. Yung, M.R. Gilbert, K.A. Aldape, P.Y. Wen, H.A. Fine, M. Mehta, L.M. Deangelis, F. Lieberman, T.F. Cloughesy, H.I. Robins, J. Dancey, and M.D. Prados A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol. 12 2010 95 103
22. L. Sasongko, J.M. Link, M. Muzi, D.A. Mankoff, X. Yang, A.C. Collier, S.C. Shoner, and J.D. Unadkat Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography Clin. Pharmacol. Ther. 77 2005 503 514
23. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr.; L.W. Fu, S.V. Ambudkar, and Z.S. Chen Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res. 67 2007 11012 11020
24. W.J. Slichenmyer, W.L. Elliott, and D.W. Fry CI-1033, a pan-erbB tyrosine kinase inhibitor Semin. Oncol. 28 2001 80 85
25. J.S. Smith, I. Tachibana, S.M. Passe, B.K. Huntley, T.J. Borell, N. Iturria, J.R. O'Fallon, P.L. Schaefer, B.W. Scheithauer, C.D. James, J.C. Buckner, and R.B. Jenkins PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme J. Natl. Cancer Inst. 93 2001 1246 1256
26. A. Tamaki, C. Ierano, G. Szakacs, R.W. Robey, and S.E. Bates The controversial role of ABC transporters in clinical oncology Essays Biochem. 50 2011 209 232
27. S.C. Tang, J.S. Lagas, N.A. Lankheet, B. Poller, M.J. Hillebrand, H. Rosing, J.H. Beijnen, and A.H. Schinkel Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 130 2012 223 233
28. M.J. van den Bent, A.A. Brandes, R. Rampling, M.C. Kouwenhoven, J.M. Kros, A.F. Carpentier, P.M. Clement, M. Frenay, M. Campone, J.F. Baurain, J.P. Armand, M.J. Taphoorn, A. Tosoni, H. Kletzl, B. Klughammer, D. Lacombe, and T. Gorlia Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J. Clin. Oncol. 27 2009 1268 1274
29. C.C. Wagner, M. Bauer, R. Karch, T. Feurstein, S. Kopp, P. Chiba, K. Kletter, W. Löscher, M. Müller, M. Zeitlinger, and O. Langer A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET J. Nucl. Med. 50 2009 1954 1961
30. J.E. Ward, and W.M. Stadler Pazopanib in renal cell carcinoma Clin. Cancer Res. 16 2012 5923 5927
31. M.S. Warren, N. Zerangue, K. Woodford, L.M. Roberts, E.H. Tate, B. Feng, C. Li, T.J. Feuerstein, J. Gibbs, B. Smith, S.M. de Morais, W.J. Dower, and K.J. Koller Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human Pharmacol. Res. 59 2009 404 413
32. 11C-labeled topotecan using small-animal positron emission tomography Nucl. Med. Biol. 38 2011 707 714
33. J.J. Yang, M.N. Milton, S. Yu, M. Liao, N. Liu, J.T. Wu, L. Gan, S.K. Balani, F.W. Lee, S. Prakash, and C.Q. Xia P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor Drug Metab. Lett. 4 2010 201 212